ストックスクリーナーアプリを入手
0.86
1.83%
-0.016
アフターアワーズ：
.87
0.01
+1.16%
前日終値:
$0.876
開ける：
$0.914
24時間の取引高:
83,233
Relative Volume:
0.61
時価総額：
$4.77M
収益：
-
当期純損益:
$-16.63M
株価収益率:
-2.00
EPS:
-0.43
ネットキャッシュフロー:
$-21.84M
1週間 パフォーマンス:
+10.81%
1か月 パフォーマンス:
-39.01%
6か月 パフォーマンス:
-60.73%
1年 パフォーマンス:
-89.22%
1日の値動き範囲:
$0.85
$0.914
1週間の範囲:
$0.7233
$0.914
52週間の値動き範囲:
$0.7233
$10.05
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
名前
Brainstorm Cell Therapeutics Inc
セクター
電話
201-488-0460
住所
1325 AVENUE OF AMERICAS, NEW YORK, NY
BCLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.86 | 4.77M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-04 | アップグレード | Maxim Group | Hold → Buy |
| 2020-11-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-12-19 | 繰り返されました | Maxim Group | Buy |
| 2015-12-22 | 繰り返されました | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
Brainstorm Cell Therapeutics adjusts quorum requirement By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm seeks FDA OK to launch NurOwn Phase 3b trial in ALS - ALS News Today
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
BrainStorm advances ALS therapy with FDA trial submission By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BrainStorm advances ALS therapy with FDA trial submission - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Nasdaq
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Reports 2024 Financial Results - TipRanks
BrainStorm Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com Canada
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting By Investing.com - Investing.com South Africa
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Nasdaq
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday - Defense World
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Brainstorm Cell Therapeutics gains extension from Nasdaq - Investing.com
Brainstorm Cell Therapeutics gains extension from Nasdaq By Investing.com - Investing.com UK
BrainStorm Cell Therapeutics Granted Compliance Extension from N - GuruFocus.com
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - MarketScreener
BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled - Stock Titan
BrainStorm receives Nasdaq listing extension to June 30 - Investing.com
BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - The Malaysian Reserve
Stem Cell Therapy Market to Witness a Paradigm Shift in Growth by 2025-2032 - newstrail.com
Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - MSN
Protara Therapeutics (NASDAQ:TARA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Contrast - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics Inc. to Host Earnings Call - ACCESS Newswire
Brainstorm Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expands By 21.3% - Defense World
Innovations in Stem Cell Therapy Market: Transforming - openPR
INVESTOR ALERT: Levi & Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024BCLI - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBCLI - ACCESS Newswire
Brainstorm Cell Therapeutics Inc (BCLI) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):